We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).

We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.

Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.

Advanced search
Date range (dd-mm-yyyy)

Redx Pharma

Key Phase II data for lead assets expected during H223

Update | 30 January 2023

HUTCHMED

Takeda licenses fruquintinib in $1.13bn ex-China deal

Lighthouse | 24 January 2023

Avacta

AVA6000 shows signs of successful tumour targetting

Lighthouse | 17 January 2023

Arecor Therapeutics

Hikma licence milestone achieved

Update | 13 January 2023

ANGLE

FY22: a year of two very distinct halves

Lighthouse | 05 January 2023

Allergy Therapeutics

Annual report and accounts delayed, shares suspended

Lighthouse | 29 December 2022

Arecor Therapeutics

Getting the chemistry right

Outlook | 20 December 2022

Redx Pharma

Laying the foundations for further delivery in 2023

Lighthouse | 20 December 2022

HUTCHMED

First steps towards fruquintinib availability in the US

Lighthouse | 19 December 2022

Avacta

Diagnostics business back into the spotlight

Update | 13 December 2022
1 2 3 4 5 6 7 8 9 10 >
348 results found.